Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS).

Guillermo Velasco,Álvaro Ruiz-Granados,Òscar Reig,Francesco Massari,Miguel Ángel Climent Duran,Elena Verzoni,Jeffrey Graham,Roberto Llarena,Michele De Tursi,Frede Donskov,Clara Iglesias,Hardev Pandha,Xavier Garcia-del-Muro,Giuseppe Procopio,Stéphane Oudard,Daniel Castellano,Laurence Albiges

Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS).

2020

Guillermo Velasco
Álvaro Ruiz-Granados
Òscar Reig
Francesco Massari
Miguel Ángel Climent Duran
Elena Verzoni
Jeffrey Graham
Roberto Llarena
Michele De Tursi
Frede Donskov
Clara Iglesias
Hardev Pandha
Xavier Garcia-del-Muro
Giuseppe Procopio
Stéphane Oudard
Daniel Castellano
Laurence Albiges

701Background: There are no available data on the usefulness of targeted therapy (TT) as the first-line treatment for patients with RCC recurrence after AS. We aim to explore the outcomes of system...

Keywords:

Adjuvant
Oncology
Systemic therapy
Targeted therapy
Pathology
Renal cell carcinoma
Internal medicine
Sunitinib
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations